Shannan R. Tujios

Dr. Shannan R. Tujios


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Hepatology
Verified
Journal Article
Open access
RSR. Todd Stravitz
R. Todd Stravitz
RFRobert J. Fontana
Robert J. Fontana
CKConstantine Karvellas
Constantine Karvellas
VDValerie Durkalski
Valerie Durkalski
BMBrendan McGuire
Brendan McGuire
FGfor the Acute Liver Failure Study Group
for the Acute Liver Failure Study Group
Acute liver failure (ALF) describes a clinical syndrome of rapid hepatocyte injury leading to liver failure manifested by coagulopathy and encephalopathy in the absence of pre-existing cirrhosis. The hallmark diagnostic features are a prolonged prothrombin time (ie, an international normalized ratio of prothrombin time of ≥1.5) and any degree of mental status alteration (HE). As a rare, orphan disease, it seemed an obvious target for a multicenter network. The Acute Liver Failure Study Group (ALFSG) began in 1997 to more thoroughly study and understand the causes, natural history, and management of ALF. Over the course of 22 years, 3364 adult patients were enrolled in the study registry (2614 ALF and 857 acute liver injury—international normalized ratio 2.0 but no encephalopathy—ALI) and >150,000 biosamples collected, including serum, plasma, urine, DNA, and liver tissue. Within the Registry study sites, 4 prospective substudies were conducted and published, 2 interventional (N-acetylcysteine and ornithine phenylacetate), 1 prognostic [13C-methacetin breath test (MBT)], and 1 mechanistic (rotational thromboelastometry). To review ALFSG’s accomplishments and consider next steps, a 2-day in-person conference was held at UT Southwestern Medical Center, Dallas, TX, entitled “Acute Liver Failure: Science and Practice,” in May 2022. To summarize the important findings in the field, this review highlights the current state of understanding of ALF and, more importantly, asks what further studies are needed to improve our understanding of the pathogenesis, natural history, and management of this unique and dramatic condition.

27 September 2011 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
RTRyan M. Taylor
Ryan M. Taylor
STShannan R. Tujios
Shannan R. Tujios
KJKartik Jinjuvadia
Kartik Jinjuvadia
TDTimothy Davern
Timothy Davern
OSObaid S. Shaikh
Obaid S. Shaikh
RFRobert J. Fontana
Robert J. Fontana

1 May 2013 in Current Opinion in Gastroenterology
Verified
Journal Article
Closed access
STShannan R. Tujios
Shannan R. Tujios
WLWilliam M. Lee
William M. Lee

7 October 2014 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
SMSean T. McCarthy
Sean T. McCarthy
STShannan R. Tujios
Shannan R. Tujios
RFRobert J. Fontana
Robert J. Fontana
SRSahand Rahnama-Moghadam
Sahand Rahnama-Moghadam
BEB. Joseph Elmunzer
B. Joseph Elmunzer
CPCyrus R. Piraka
Cyrus R. Piraka

27 February 2023 in Liver Transplantation
Verified
Journal Article
Closed access
TEThomas Enke
Thomas Enke
SLSherry Livingston
Sherry Livingston
JRJody Rule
Jody Rule
TSTodd Stravitz
Todd Stravitz
JRJorge Rakela
Jorge Rakela
DGDaniel Ganger
Daniel Ganger
Autoimmune hepatitis is a common cause of acute liver failure. Treatment includes steroids for acute liver injury and liver transplantation in those who fail to respond or develop acute liver failure. The aim of this study is to further characterize acute liver failure secondary to autoimmune hepatitis and identify variables that predict 21-day transplant-free survival. This study included adults hospitalized with acute liver failure enrolled in the Acute Liver Failure Study Group Registry between 1998 and 2019 from 32 centers within the US. The etiology of all cases was reviewed by the Adjudication Committee, and all cases identified as autoimmune hepatitis were included. Acute liver injury was defined as an INR ≥2.0 without encephalopathy and acute liver failure as INR ≥ 1.5 with encephalopathy. Laboratory and clinical data were reviewed. Variables significantly associated with 21-day transplant-free survival were used to develop a multivariable logistic regression model. A total of 193 cases of acute liver failure secondary to autoimmune hepatitis were identified and reviewed. There were 161 patients (83.4%) diagnosed with acute liver failure on enrollment, and 32 (16.6%) developed acute liver failure during hospitalization. At 21 days, 115 (59.6%) underwent liver transplantation, 28 (14.5%) had transplant-free survival, and 46 (23.8%) died before liver transplantation. Higher admission values of bilirubin, INR, and coma grade were associated with worse outcomes. A prognostic index incorporating bilirubin, INR, coma grade, and platelet count had a concordance statistic of 0.84. Acute liver failure secondary to autoimmune hepatitis is associated with a high short-term mortality. We developed a model specifically for autoimmune hepatitis that may be helpful in predicting 21-day transplant-free survival and early identification of patients in need of expedited liver transplant evaluation.

1 October 2015 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
STShannan R. Tujios
Shannan R. Tujios
SRSahand Rahnama-Moghadam
Sahand Rahnama-Moghadam
JEJoseph B. Elmunzer
Joseph B. Elmunzer
RKRichard Kwon
Richard Kwon
ASAmit G. Singal
Amit G. Singal
CPCyrus R. Piraka
Cyrus R. Piraka
Goals: To describe the short-term and long-term outcomes in 34 consecutive decompensated cirrhotic patients with symptomatic gallbladder disease undergoing transpapillary gallbladder stent (TGS) placement. Background: Endoscopic TGS placement is a minimally invasive means of treating symptomatic gallbladder disease in poor surgical candidates. Study: Between June 2005 and June 2011, 34 patients with cirrhosis and symptomatic gallbladder disease underwent attempted TGS placement. Results: Median patient age was 52 years, 56% were hospitalized, and 48% were listed for liver transplantation. The median model for end-stage liver disease (MELD) score was 15 (range, 6 to 40) and 88% were Child-Turcotte-Pugh class B/C. A double pigtailed stent was successfully placed in 94% of the patients. At 1-month follow-up, clinical improvement was noted in 82% of the treated subjects and the MELD scores in 14 of 22 (64%) evaluable subjects improved or stabilized. Actuarial transplant-free survival was 53% in the liver transplant candidates with a mean follow-up of 352 days, whereas survival was 44% in the 18 nontransplant candidates with a mean follow-up of 1.5 years. Periprocedural complications included pancreatitis in 5 patients, cholangitis in 3, and 1 patient with cystic duct perforation. In addition, 2 subjects had symptomatic bleeding from traumatic duodenal ulcerations 2 years after TGS placement that necessitated stent removal. Conclusions: Endoscopic TGS placement was technically feasible in 94% of decompensated cirrhotics and was associated with a relatively low rate of periprocedural (26%) and long-term complications (6%). Stabilization or improvement in clinical status and MELD scores was seen in the majority of treated patients.